Achieve Life Sciences, Inc. (ACHV): Price and Financial Metrics


Achieve Life Sciences, Inc. (ACHV): $3.29

-0.05 (-1.50%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ACHV to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ACHV Stock Price Chart Interactive Chart >

Price chart for ACHV

ACHV Price/Volume Stats

Current price $3.29 52-week high $9.21
Prev. close $3.34 52-week low $3.19
Day low $3.19 Volume 35,900
Day high $3.34 Avg. volume 56,684
50-day MA $4.68 Dividend yield N/A
200-day MA $6.41 Market Cap 31.85M

Achieve Life Sciences, Inc. (ACHV) Company Bio


Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation aids in the United States and internationally. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.


ACHV Latest News Stream


Event/Time News Detail
Loading, please wait...

ACHV Latest Social Stream


Loading social stream, please wait...

View Full ACHV Social Stream

Latest ACHV News From Around the Web

Below are the latest news stories about ACHIEVE LIFE SCIENCES INC that investors may wish to consider to help them evaluate ACHV as an investment opportunity.

Achieve Life Sciences Announces Participation at Fall Investor Conferences

SEATTLE and VANCOUVER, British Columbia, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will be participating at the Lake Street Best Ideas Growth Conference and the Ladenburg Thalmann Healthcare Conference. The conferences are taking place at the Yale Club and Sofitel Hotel in New

Yahoo | September 7, 2022

Ladenburg Thalmann & Co. Remains a Buy on Achieve Life Sciences (ACHV)

Ladenburg Thalmann & Co. analyst Michael Higgins maintained a Buy rating on Achieve Life Sciences (ACHV - Research Report) today and set a price target of $35.00. The company's shares closed last Friday at $5.00.According to TipRanks, Higgins is a 4-star analyst with an average return of 5.8% and a 31.63% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Marinus, Astria Therapeutics, and Zynerba Pharmaceuticals.Achieve Life Sciences has an analyst consensus of Strong Buy, with a price target consensus of $26.67, which is a 433.40% upside from current levels. In a report released today, H.C.

Brian Anderson on TipRanks | August 15, 2022

ACHV: Autumn Enrollment Completion for ORCA-3

By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT Second Quarter 2022 Results Achieve Life Sciences, Inc. (NASDAQ:ACHV) reported second quarter 2022 results in a press release and held a conference call after market close on August 11, 2022. The company concurrently filed its Form 10-Q with the SEC. Since its first quarter update, Achieve has begun its long-awaited vaping

Yahoo | August 15, 2022

Achieve Reports Financial Results for Second Quarter 2022 and Provides Corporate Update

Company to host conference call at 4:30 PM EDT today, August 11, 2022SEATTLE and VANCOUVER, British Columbia, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced second quarter 2022 financial results and provided an update on the cytisinicline clinical development program. Recent Events & Hi

Yahoo | August 11, 2022

Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 11, 2022

SEATTLE and VANCOUVER, British Columbia, July 28, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will report its second quarter financial results and provide an update on the cytisinicline development program on Thursday, August 11, 2022, at 4:30 PM EDT. To access the webcast, please use the

Yahoo | July 28, 2022

Read More 'ACHV' Stories Here

ACHV Price Returns

1-mo -27.85%
3-mo -32.99%
6-mo -56.42%
1-year -61.29%
3-year -90.03%
5-year -99.19%
YTD -57.71%
2021 -3.95%
2020 -23.57%
2019 -56.21%
2018 -90.97%
2017 -75.64%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.54 seconds.